Capsid Proteins

• 

  Subject Areas on Research

  • A TGF-β1 genetic variant at the miRNA187 binding site significantly modifies risk of HPV16-associated oropharyngeal cancer. 
  • A new EV71 VP3 epitope in norovirus P particle vector displays neutralizing activity and protection in vivo in mice. 
  • A novel immunocompetent murine tumor model for the evaluation of RCAd-enhanced RDAd transduction efficacy. 
  • Acute hepatitis due to epstein-barr virus in an immunocompetent patient. 
  • Adenovirus capsid-display of the retro-oriented human complement inhibitor DAF reduces Ad vector-triggered immune responses in vitro and in vivo. 
  • Base-pairing potential identified by in vitro selection predicts the kinked RNA backbone observed in the crystal structure of the alfalfa mosaic virus RNA-coat protein complex. 
  • Characterization of the Adeno-Associated Virus 1 and 6 Sialic Acid Binding Site. 
  • Conformational and nucleic acid binding studies on the synthetic nucleocapsid protein of HIV-1. 
  • Cross-dressing the virion: the transcapsidation of adeno-associated virus serotypes functionally defines subgroups. 
  • Detection of antibodies against Turkey astrovirus in humans. 
  • Development of Patient-specific AAV Vectors After Neutralizing Antibody Selection for Enhanced Muscle Gene Transfer. 
  • Engineering AAV receptor footprints for gene therapy. 
  • Enhanced efficacy from gene therapy in Pompe disease using coreceptor blockade. 
  • Epstein-Barr virus antibodies in whole blood spots: a minimally invasive method for assessing an aspect of cell-mediated immunity. 
  • Evaluation of recombinant adenovirus vaccines based on glycoprotein D and truncated UL25 against herpes simplex virus type 2 in mice. 
  • High-level synthesis of biologically active reovirus protein sigma 1 in a mammalian expression vector system. 
  • Human papillomavirus seropositivity synergizes with MDM2 variants to increase the risk of oral squamous cell carcinoma. 
  • Immune mechanisms responsible for vaccination against and clearance of mucosal and lymphatic norovirus infection. 
  • Intra- and inter-subunit disulfide bond formation is nonessential in adeno-associated viral capsids. 
  • Mapping and Engineering Functional Domains of the Assembly-Activating Protein of Adeno-associated Viruses. 
  • Mapping the Structural Determinants Required for AAVrh.10 Transport across the Blood-Brain Barrier. 
  • Mechanisms of bacteriophage inactivation via singlet oxygen generation in UV illuminated fullerol suspensions. 
  • Molecular analysis of adenovirus isolates from vaccinated and unvaccinated young adults. 
  • Molecular typing of clinical adenovirus specimens by an algorithm which permits detection of adenovirus coinfections and intermediate adenovirus strains. 
  • Mucosal vaccine targeting improves onset of mucosal and systemic immunity to botulinum neurotoxin A. 
  • Multiple roles for sialylated glycans in determining the cardiopulmonary tropism of adeno-associated virus 4. 
  • Mutations of basic amino acids of NCp7 of human immunodeficiency virus type 1 affect RNA binding in vitro. 
  • Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1. 
  • Naturally occurring amino acid polymorphisms in human immunodeficiency virus type 1 (HIV-1) Gag p7(NC) and the C-cleavage site impact Gag-Pol processing by HIV-1 protease. 
  • Novel adenovirus vectors 'capsid-displaying' a human complement inhibitor. 
  • Phage display screening for peptides that inhibit polyglutamine aggregation. 
  • Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. 
  • Potency of a Scalable Nanoparticulate Subunit Vaccine. 
  • Preservation of motor function by inhibition of CD8+ virus peptide-specific T cells in Theiler's virus infection. 
  • Proteins of purified Epstein-Barr virus. 
  • Replication-attenuated Human Adenoviral Type 4 vectors elicit capsid dependent enhanced innate immune responses that are partially dependent upon interactions with the complement system. 
  • Resolving Adeno-Associated Viral Particle Diversity With Charge Detection Mass Spectrometry. 
  • Rotavirus RNA polymerase requires the core shell protein to synthesize the double-stranded RNA genome. 
  • Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes. 
  • Specific binding of HIV-1 nucleocapsid protein to PSI RNA in vitro requires N-terminal zinc finger and flanking basic amino acid residues. 
  • Stimulation of Ki-ras ribozyme activity by RNA binding protein, NCp7, in vitro and in pancreatic tumor cell line, capan 1. 
  • Structure-based high-throughput epitope analysis of hexon proteins in B and C species human adenoviruses (HAdVs). 
  • Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion. 
  • Surface loop dynamics in adeno-associated virus capsid assembly. 
  • Synonymous codon usage analysis of hand, foot and mouth disease viruses: A comparative study on coxsackievirus A6, A10, A16, and enterovirus 71 from 2008 to 2015. 
  • Systemic gene transfer to skeletal muscle using reengineered AAV vectors. 
  • The differentiated form of nasopharyngeal carcinoma contains Epstein-Barr virus DNA. 
  • Turnip yellow mosaic virus as a chemoaddressable bionanoparticle. 
  • Tyrosine cross-linking reveals interfacial dynamics in adeno-associated viral capsids during infection.